BioSense gets Asia rights to Rexahn's pancreatic cancer therapy

BioSense gained exclusive rights to develop and commercialize Rexahn's RX-3117 to treat and prevent pancreatic cancer in Singapore, China, Hong Kong, Macau and Taiwan.

Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) will receive $3 million up front and is eligible for $226 million in development, regulatory and commercial milestones, plus low double-digit to mid-teen royalties...